Equities

ValiRx PLC

ValiRx PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)3.55
  • Today's Change-0.300 / -7.79%
  • Shares traded888.76k
  • 1 Year change-65.37%
  • Beta0.9439
Data delayed at least 20 minutes, as of Mar 28 2024 16:19 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ValiRx plc is a life science company. The Company is focused on early-stage cancer therapeutics and women's health. The Company provides the scientific, financial and commercial framework to enable the rapid translation of science into clinical development. Its product pipeline includes VAL201, VAL301, VAL401 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. Its VAL301 for the treatment of women with endometriosis. BC201 is a combination of the peptide ingredient of VAL201/VAL301 with active components to dampen this excessive immune response and consequently improve severe symptoms of Covid-19. It operates through divisional companies, including ValiPharma, ValiSeek, Cytolytix Limited, and Inaphaea BioLabs Limited.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-2.41m
  • Incorporated2000
  • Employees8.00
  • Location
    ValiRx PLCEliot Park Innovation Centre4 Barling WayNUNEATON CV10 7RHUnited KingdomGBR
  • Phone+44 247 679 6496
  • Fax+44 203 008 4415
  • Websitehttps://www.valirx.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
VAL:LSE since
announced
Transaction
value
Imagen Therapeutics Ltd-Scientific AssetsDeal completed14 Jun 202314 Jun 2023Deal completed-60.99%--
Data delayed at least 20 minutes, as of Mar 28 2024 16:19 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Evgen Pharma PLC838.00k-3.35m2.41m7.00--0.6113--2.87-0.0122-0.01220.00310.01430.1406--1.81119,714.30-56.25-42.37-60.57-46.32-----400.12-2,324.84----0.00-------48.10---32.24--
Hellenic Dynamics PLC-100.00bn-100.00bn3.21m25.00--4.23----------0.006----------------------------0.3029--------------
Fusion Antibodies PLC1.58m-2.84m3.58m50.00--1.53--2.26-0.0861-0.08610.04360.02450.52293.151.8831,580.00-93.94-31.29-130.56-37.72-7.4142.58-179.67-48.252.32--0.0313---39.551.52-116.33---23.83--
IXICO PLC6.67m-1.18m3.92m89.00--0.3426--0.5876-0.0244-0.02440.1380.23640.4822--2.8274,887.64-8.524.35-9.575.3349.0662.09-17.676.61----0.03270.00-22.894.32-214.15--92.12--
Genflow Biosciences PLC0.00-1.18m4.31m0.00--2.51-----0.004-0.0040.000.00590.00-------48.01---51.61-------------6,299.750.00-------35.13------
Oxford Cannabinoid Tchnlgs Hldngs PLC0.00-4.24m4.68m7.00--2.12-----0.0044-0.00440.000.0020.00----0.00-82.98-56.41-104.70-66.13------------0.00-------26.16------
ValiRx Plc0.00-2.41m4.70m8.00--0.864-----0.0256-0.02560.000.04110.00----0.00-69.67-58.85-69.21-68.96-----------575.810.0072-------55.87------
BSF Enterprise PLC12.94k-1.50m6.10m4.00--1.25--471.17-0.0159-0.01590.00010.0470.00282.110.08373,235.00-32.30---34.46---451.16---11,600.08--8.16-154.860.0313-------61.40------
Cizzle Biotechnology Holdings PLC0.00-953.00k6.73m67.00--2.57-----0.003-0.0030.000.00720.00-------35.53-134.34-37.22-227.22------------0.00------76.74------
Data as of Mar 28 2024. Currency figures normalised to ValiRx PLC's reporting currency: UK Pound GBX
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.